EFFECT OF VEDOLIZUMAB DOSE ESCALATION ON RECAPTURING RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：9
|
作者：
Shivashankar, Raina
Ladd, Antonio H. Mendoza
Grace, Rory
Aberra, Faten
Lichtenstein, Gary R.
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)30608-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
304
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [21] The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
    Huseynzada, Sinakhanim
    Inel, Tuba Yuce
    Hajiyev, Farid
    Avsar, Aydan Koken
    Balci, Ali
    Akpinar, Hale
    Onen, Fatos
    Sari, Ismail
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2023, 10 (02) : 50 - +
  • [22] Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
    Scarozza, Patrizio
    De Cristofaro, Elena
    Scucchi, Ludovica
    Rocchetti, Irene
    Marafini, Irene
    Neri, Benedetto
    Salvatori, Silvia
    Biancone, Livia
    Calabrese, Emma
    Monteleone, Giovanni
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 10
  • [23] Metabolomic predictors of response to vedolizumab in Inflammatory Bowel Disease
    Reider, S.
    Watschinger, C.
    Koch, R.
    Tilg, H.
    Moschen, A.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I522 - I522
  • [24] Endoscopic and Histologic Response and Remission in Inflammatory Bowel Disease Patients Initiating Vedolizumab
    Christensen, Britt
    Rubin, David T.
    Goeppinger, Sarah
    Colman, Ruben J.
    Yarur, Andres
    Hirsch, Ayal
    Bocheneck, Ashley
    Wichmann, Alana
    Sakuraba, Atsushi
    Cohen, Russell
    Siddiqui, Dania
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S783 - S784
  • [25] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [26] Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response
    Samaan, Mark A.
    Birdi, Siddharth
    Morales, Maria Sierra
    Honap, Sailish
    Tamilarasan, Aravind Gokul
    Cunningham, Georgina
    Koumoutsos, Ioannis
    Ray, Shuvra
    Mawdsley, Joel
    Anderson, Simon H. C.
    Sanderson, Jeremy
    Irving, Peter M.
    FRONTLINE GASTROENTEROLOGY, 2020, 11 (03) : 188 - 193
  • [27] SAFETY OF VEDOLIZUMAB USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Shivashankar, Raina
    Ladd, Antonio H. Mendoza
    Grace, Rory
    Aberra, Faten
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2017, 152 (05) : S585 - S585
  • [28] Vedolizumab Use in Pediatric Patients With Inflammatory Bowel Disease
    Singh, Namita
    Patel, Minesh
    Rabizadeh, Shervin
    Dubinsky, Marla
    GASTROENTEROLOGY, 2015, 148 (04) : S72 - S72
  • [29] De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
    Thomas, Pepijn W. A.
    Smits, Lisa J. T.
    Te Groen, Maarten
    West, Rachel L.
    Russel, Maurice G. V. M.
    Jansen, Jeroen M.
    Romkens, Tessa E. H.
    Hoentjen, Frank
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (05) : 488 - 495
  • [30] THE EFFECT OF VEDOLIZUMAB ON COLONIC MICROBIOTA COMPOSITION IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE
    Altomare, Annamaria
    Rocchi, Giulia
    Balestrieri, Paola
    Tullio, Alessandro
    Putignani, Lorenza
    Gori, Manuele
    Guarino, Michele Pier Luca
    Cicala, Michele
    GASTROENTEROLOGY, 2023, 164 (06) : S918 - S919
12345